Palivizumab: Moderate reduction in hospitalisation rate

Prescrire International

Volumn 13, Issue 74, 2004, Pages 213-216

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PALIVIZUMAB; PLACEBO; ANTIVIRUS AGENT;

ARTICLE; CANADA; CHILD CARE; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; CONGENITAL HEART DISEASE; DISEASE SEVERITY; DRUG COST; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FOLLOW UP; FRANCE; GESTATIONAL AGE; HEMATOMA; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INFANT; INFANT MORTALITY; INJECTION SITE REACTION; INTENSIVE CARE; LICENCE; LOWER RESPIRATORY TRACT INFECTION; LUNG DYSPLASIA; MEDICAL DOCUMENTATION; META ANALYSIS; PATIENT SELECTION; PREMATURITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK ASSESSMENT; RISK REDUCTION; SKIN EDEMA; SPAIN; TREATMENT INDICATION; UNITED STATES; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; ECONOMICS; NEWBORN; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CANADA; CHILD; CHILD, PRESCHOOL; CORONARY DISEASE; DOUBLE-BLIND METHOD; DRUG APPROVAL; FRANCE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS; SPAIN; UNITED STATES;

EID: 16544366922     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Prescrire Editorial Staff "RSV infections and bronchiolitis: who qualifies for prevention" Prescrire Int 2000; 9 (50): 173.
2. Prescrire Rédaction "Vacciner les enfants contre la grippe" Rev Prescrire 2003; 23 (245): 852-856.
3. Prescrire Editorial Staff "Palivizumab in prevention of bronchiolitis: moderate efficacy in some infants" Prescrire Int 2000; 9 (50): 171-174.
4. French Transprency Commission "Avis de la commission - Synagis" 6 November 2002: 6 pages.
5. Lacaze-Masmonteil T et al. "Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with palivizumab as RSV prophylaxis" Pediatr Pulmonol 2002; 34 (3): 181-188.
6. Pedraz C et al. "Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants" Pediatr Infect Dis J 2003; 22 (9): 823-827.
7. Palivizumab Outcomes Registry Study Group "Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from the palivizumab outcomes registry" Pediatr Pulmonol 2003; 35 (6): 484-489.
8. Romero JR "Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage" Pediatr Infect Dis J 2003; 22 (2) (suppl.): 46-54.
9. Oh PI et al. "Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes" Pediatr Infect Dis J 2002; 21 (6): 512-518.
10. Singleton R et al. "Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska native infants" Pediatr Infect Dis J 2003; 22 (6): 540-545.
11. Feltes TF et al. "Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in yound children with hemodynamically significant congenital heart disease" J Pediatr 2003; 143 (4): 532-540.
12. Comité consultatif national de l'immunisation "Délaration concernant l'usage recommendé de l'anticorps monoclonal anti-VRS (palivizumab)" RMTC 2003; 29: 1-13.
13. Agence française de sécurité des produits de santé "Lettre à la revue Prescrire" 30 April 2003: 1 page.
14. "Synagis°" In: "Physicians' Desk Reference" 58th ed, Thomson-PDR, Montvalle 2004: 1909-1910.
15. Lacaze-Masmonteil T et al. "Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection" Drug Safety 2003; 26 (4): 283-291.